Non-alcoholic fatty liver disease has no early signs. Is your liver at risk? Expert reveals these simple tests could save your life!

Princeton: Bristol Myers Squibb has announced that the European Commission (EC) has approved Opdivo (nivolumab) plus Yervoy ...

Topline results were announced from a phase 3 trial evaluating durvalumab in combination with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) ...

US pharma major Bristol Myers Squibb has announced that the European Commission (EC) has approved Opdivo (nivolumab) plus ...

AstraZeneca (AZ) has shared positive results from a late-stage trial of its Imfinzi (durvalumab)-based perioperative regimen ...

Bristol Myers Squibb has won the European Commission's expanded approval of its Opdivo plus Yervoy cancer-drug combination for early use in certain patients with liver cancer. Bristol Myers on Friday ...

ScaleUps Ventures, a leading UK-based Health and Social Care startup accelerator announced its 2025 cohort of 11 pioneering companies to deliver on the innovation needs of the NHS and private sector.

Four new officers and four new board members will be installed immediately upon conclusion of the 2025 Annual Meeting of the American Academy of Dermatology. The officers and board members are all ...

Squibb announced that the European Commission has approved Opdivo plus Yervoy for the first-line treatment of adult ...

An interval of fewer than 30 days between the last immunotherapy dose and the liver transplant increases the rejection risk ...

PD-L1 在肿瘤细胞中常常过度表达，它就像肿瘤的 “盾牌”，与浸润免疫细胞上的 PD-1 相互作用，帮助肿瘤细胞成功逃避人体免疫系统的 “追捕”。虽然肿瘤 PD-L1 表达被视为预测免疫治疗反应的 “潜力股”，但它并非完美无缺。因此，深入探究调节 PD-L1 表达的分子机制，成为了提高肝癌免疫治疗效果的关键 “钥匙”。

Ipsen's 2024 dividend per share amounted to EUR 1.20. We view Ipsen's shareholder distributions as mixed as many other biotechnology companies under our coverage do not pay dividends. We anticipate ...